Key facts
- It has raised $18.8M.
- Notable investors include UniSuper Superannuation Fund, Iomar Barrett, Macquarie University Incubator, Uniseed.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Celosia Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Celosia Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Celosia Therapeutics
Developer of neurotherapeutic interventions designed for treatment-resistant neurodegenerative conditions. The company modifies the neuronal microenvironment through targeted molecular approaches, focusing on diseases such as ALS, Alzheimer's, frontotemporal dementia, and Dravet syndrome, and incorporates translational research, disease-specific biomarkers, and preclinical validation strategies, enabling neuroscience researchers and clinical developers to explore novel therapeutic pathways for disorders with limited or no existing treatment options.
- Sector
- Healthcare
- HQ
- Macquarie Park, Australia
- Founded
- 2022
- Employees
- 4
- Website
- celosiatx.com/
- Ownership
- Privately Held (backing)
Celosia Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Celosia Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Celosia Therapeutics in its N-PORT filings yet. We sweep new filings monthly.